- Home
- PSTL vs ZNTL Comparison
PSTL vs ZNTL Comparison
Compare PSTL & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTL
- ZNTL
- Stock Information
- Founded
- PSTL 2018
- ZNTL 2014
- Country
- PSTL United States
- ZNTL United States
- Employees
- PSTL N/A
- ZNTL N/A
- Industry
- PSTL Real Estate Investment Trusts
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- PSTL Real Estate
- ZNTL Health Care
- Exchange
- PSTL Nasdaq
- ZNTL Nasdaq
- Market Cap
- PSTL 329.8M
- ZNTL 105.8M
- IPO Year
- PSTL 2019
- ZNTL 2020
- Fundamental
- Price
- PSTL $14.85
- ZNTL $1.37
- Analyst Decision
- PSTL Strong Buy
- ZNTL Buy
- Analyst Count
- PSTL 1
- ZNTL 7
- Target Price
- PSTL $16.50
- ZNTL $8.60
- AVG Volume (30 Days)
- PSTL 179.1K
- ZNTL 1.4M
- Earning Date
- PSTL 08-05-2025
- ZNTL 08-08-2025
- Dividend Yield
- PSTL 6.52%
- ZNTL N/A
- EPS Growth
- PSTL 176.54
- ZNTL N/A
- EPS
- PSTL 0.28
- ZNTL N/A
- Revenue
- PSTL $81,235,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- PSTL $19.86
- ZNTL N/A
- Revenue Next Year
- PSTL $10.14
- ZNTL N/A
- P/E Ratio
- PSTL $52.57
- ZNTL N/A
- Revenue Growth
- PSTL 23.36
- ZNTL N/A
- 52 Week Low
- PSTL $12.26
- ZNTL $1.01
- 52 Week High
- PSTL $15.42
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- PSTL 60.00
- ZNTL 53.19
- Support Level
- PSTL $14.54
- ZNTL $1.29
- Resistance Level
- PSTL $15.08
- ZNTL $1.43
- Average True Range (ATR)
- PSTL 0.25
- ZNTL 0.09
- MACD
- PSTL -0.05
- ZNTL 0.01
- Stochastic Oscillator
- PSTL 70.07
- ZNTL 77.02
About PSTL Postal Realty Trust Inc.
Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.